6 October 2015 - Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen, today announced that Somatuline Autogel (lanreotide) Injection 120 mg (referred to as Somatuline) has been approved by Health Canada for the treatment of enteropancreatic neuroendocrine tumours in patients with Grade 1 or a subset of Grade 2 (equivalent to Ki67 < 10 per cent) unresectable, locally advanced or metastatic disease to delay progression. Enteropancreatic neuroendocrine tumours, also known as NETs, generally start in the pancreas or digestive tract and can spread to other parts of the body.

"Somatuline is a new weapon in our fight against enteropancreatic NETs, a cancer that affects 12,000 to 15,000 Canadians," said Simron Singh, Medical Oncologist and Co-Director, Susan Leslie NETs Clinic at Odette Cancer Center, Sunnybrook Health Sciences Center in Toronto. "Somatuline is one of the first treatments of its kind approved for this patient population that has demonstrated a statistically significant improvement in progression-free survival (PFS), which is a measure of how long the patient continues to live without the disease getting worse."

For more details, go to: http://www.newswire.ca/news-releases/health-canada-approves-somatuline-autogel-lanreotide-injection-for-the-treatment-of-enteropancreatic-neuroendocrine-tumours-530836431.html